Leerink Swann Downgrades Immunogen Inc. (IMGN) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Immunogen (IMGN) PT Cut to $9 at Cantor Fitzgerald
December 22, 2014 7:50 AM ESTCantor Fitzgerald analyst Mara Goldstein reiterated a Hold rating and lowered her price target on Immunogen Inc. (NASDAQ: IMGN) price target of $9.00 (from $14.00) on disappointing MARIANNE news.
Goldstein said Friday's 40% sell-off have been an overreaction but they remain on the sidelines. "The... More
Jefferies Downgrades Immunogen Inc. (IMGN) to Hold
December 19, 2014 1:19 PM ESTJefferies downgraded Immunogen Inc. (NASDAQ: IMGN) from Buy to Hold with a price target of $7.00 (from $20.00).
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $10.85 yesterday.
... MoreImmunogen (IMGN) Declines; Roche Reports Disappointing MARIANNE Trial Results
December 19, 2014 8:01 AM ESTImmunoGen, Inc.(NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche (OTC: RHHBY) has announced top-line results of its Phase III MARIANNE study.
The study evaluated three HER2-targeted regimens Kadcyla® (ado-trastuzumab emtansine) plus Perjeta® (pertuzumab), Kadcyla alone, and Herceptin® (trastuzumab) plus taxane chemotherapy in people with previously... More
